My Cart

HLA-A*02:01 & B2M & Peptide (KVLEHVVRV)

Product Inquiry

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
MertuzumabPhase 3 ClinicalJiangsu Pacific-Meinuoke Bio-Pharmaceutical Co Ltd, Institute Of Medicine Fourth Military Medical UniversityCoronavirus Disease 2019 (COVID-19); Carcinoma, Non-Small-Cell Lung
Details
MeplazumabHI6H8Phase 3 ClinicalJiangsu Pacific-Meinuoke Bio-Pharmaceutical Co Ltd, Institute Of Medicine Fourth Military Medical UniversityMalaria; Coronavirus Disease 2019 (COVID-19); Malaria, Falciparum
Details
Anti-CD147 CAR T cell therapy (Xijing Hospital)Phase 1 ClinicalGlioblastoma
Details
CD147-CAR T cell therapy (Peking University People's Hospital)Phase 1 ClinicalPeking University People'S HospitalLymphoma, T-Cell
Details
89Zr-CD147Phase 1 ClinicalSolid tumours
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyFirst Brand NameFirst Approved CountryFirst IndicationFirst Approved CompanyFirst Approved DateIndicationClinical Trial
Iodine[131I] MetuximabApprovedChengdu Huasun Biotechnology Co LtdLicartin, 利卡汀Mainland ChinaCarcinoma, HepatocellularChengdu Huasun Biotechnology Co Ltd2006-10-12Carcinoma, Hepatocellular
Details
  • Product Inquiry
  • Marketed Drug Information
  • Clinical Drug Information
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland